Innovent Biologics (IVBXF) jointly announced with Sanegene Bio USA that the preliminary results from the first-in-human, FIH, Phase 1 clinical study of IBI3016, an experimental small interfering RNA, siRNA, medicine targeting angiotensinogen mRNA, AGT, were reported at the 2025 American Heart Association, AHA, scientific sessions. Dr. Fangfang Wang from Peking University Third Hospital, delivered the moderated digital poster presentation of the study results. IBI3016 demonstrates sustained and potent AGT mRNA suppression with preliminary evidence of antihypertensive efficacy after single-dose subcutaneous administration. The clinical Phase 1 data of IBI3016 further support the potential for biannual subcutaneous dosing for the treatment of hypertension. Next-step development is scheduled to initiate soon.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IVBXF:
- Innovent Biologics Achieves 40% Revenue Growth in Q3 2025
- Innovent Biologics and Takeda Partnership Fuels Global Expansion and Strengthens Buy Rating
- Innovent Biologics announces global strategic partnership with Takeda
- Innovent Biologics Partners with Takeda for Global Cancer Therapy Development
- Innovent Biologics’ Mazdutide Approved in China for Type 2 Diabetes